New MS Drug Approved

(MedPage Today) -- The first self-administered, targeted B-cell treatment for relapsing multiple sclerosis (MS) received FDA approval on Thursday, Novartis announced.
Ofatumumab (Kesimpta), an antibody targeting CD20-positive B cells, is approved...